| Primary |
| Product Used For Unknown Indication |
64.2% |
| Maternal Exposure Timing Unspecified |
7.2% |
| Epilepsy |
4.9% |
| Drug Use For Unknown Indication |
4.3% |
| Schizoaffective Disorder |
4.1% |
| Convulsion |
3.4% |
| Pyrexia |
1.3% |
| Asthenia |
1.1% |
| Drug Exposure During Pregnancy |
1.1% |
| Dyspnoea |
1.1% |
| Bipolar Disorder |
1.0% |
| Hiv Infection |
1.0% |
| Bipolar I Disorder |
0.8% |
| Depression |
0.8% |
| Pleurisy |
0.8% |
| Schizophrenia |
0.7% |
| Systemic Lupus Erythematosus |
0.7% |
| Affective Disorder |
0.5% |
| Chorea |
0.5% |
| Grand Mal Convulsion |
0.5% |
|
| Speech Disorder Developmental |
17.5% |
| Drug Interaction |
8.2% |
| Foetal Exposure During Pregnancy |
8.2% |
| Toxicity To Various Agents |
7.2% |
| Vomiting |
7.2% |
| Status Epilepticus |
5.2% |
| Convulsion |
4.1% |
| Pancreatitis |
4.1% |
| Sedation |
4.1% |
| Hyperammonaemia |
3.1% |
| Neuroleptic Malignant Syndrome |
3.1% |
| Overdose |
3.1% |
| Pneumonia |
3.1% |
| Pyrexia |
3.1% |
| Spina Bifida |
3.1% |
| Suicidal Ideation |
3.1% |
| Syncope |
3.1% |
| Toxic Epidermal Necrolysis |
3.1% |
| Treatment Noncompliance |
3.1% |
| Urinary Incontinence |
3.1% |
|
| Secondary |
| Product Used For Unknown Indication |
21.8% |
| Epilepsy |
18.3% |
| Drug Use For Unknown Indication |
12.9% |
| Schizoaffective Disorder |
7.9% |
| Bipolar Disorder |
6.1% |
| Depression |
6.1% |
| Grand Mal Convulsion |
4.0% |
| Convulsion |
3.4% |
| Acute Myeloid Leukaemia |
2.9% |
| Mental Retardation |
2.5% |
| Metabolic Syndrome |
2.3% |
| Bipolar I Disorder |
2.0% |
| Status Epilepticus |
1.6% |
| Mania |
1.4% |
| Pyrexia |
1.4% |
| Temporal Lobe Epilepsy |
1.4% |
| Unevaluable Event |
1.1% |
| Dementia Alzheimer's Type |
0.9% |
| Drug Exposure During Pregnancy |
0.9% |
| Hypertension |
0.9% |
|
| Vaginal Ulceration |
13.9% |
| Metabolic Syndrome |
8.3% |
| Cataract |
6.9% |
| Weight Increased |
6.9% |
| Pancytopenia |
5.6% |
| Toxicity To Various Agents |
5.6% |
| Urticaria |
5.6% |
| Lupus-like Syndrome |
4.2% |
| Priapism |
4.2% |
| Respiratory Failure |
4.2% |
| Somnolence |
4.2% |
| Speech Disorder Developmental |
4.2% |
| Stevens-johnson Syndrome |
4.2% |
| Toxic Epidermal Necrolysis |
4.2% |
| Vomiting |
4.2% |
| Epistaxis |
2.8% |
| Irritability |
2.8% |
| Overdose |
2.8% |
| Petit Mal Epilepsy |
2.8% |
| Platelet Count Decreased |
2.8% |
|
| Concomitant |
| Epilepsy |
28.2% |
| Product Used For Unknown Indication |
20.8% |
| Grand Mal Convulsion |
10.1% |
| Myoclonic Epilepsy |
9.2% |
| Schizophrenia |
7.8% |
| Bipolar Disorder |
3.9% |
| Schizoaffective Disorder |
2.0% |
| Infection Prophylaxis |
1.8% |
| Drug Use For Unknown Indication |
1.6% |
| Prophylaxis |
1.5% |
| Affective Disorder |
1.4% |
| Constipation |
1.4% |
| Rheumatoid Arthritis |
1.4% |
| Schizophrenia, Paranoid Type |
1.4% |
| Type 2 Diabetes Mellitus |
1.4% |
| Pain |
1.3% |
| Bone Marrow Conditioning Regimen |
1.2% |
| Depression |
1.2% |
| Premedication |
1.1% |
| Convulsion |
1.0% |
|
| Epilepsy |
19.9% |
| White Blood Cell Count Increased |
7.6% |
| Loss Of Consciousness |
7.0% |
| White Blood Cell Count Decreased |
7.0% |
| Nausea |
6.4% |
| Vomiting |
5.3% |
| Status Epilepticus |
4.7% |
| Thrombocytopenia |
4.7% |
| Urinary Tract Infection |
4.1% |
| Platelet Count Decreased |
3.5% |
| Psychotic Disorder |
3.5% |
| Encephalopathy |
2.9% |
| Nightmare |
2.9% |
| Physical Assault |
2.9% |
| Priapism |
2.9% |
| Product Substitution Issue |
2.9% |
| Renal Impairment |
2.9% |
| Salivary Hypersecretion |
2.9% |
| Somnolence |
2.9% |
| Withdrawal Syndrome |
2.9% |
|
| Interacting |
| Product Used For Unknown Indication |
36.4% |
| Depression |
13.6% |
| Schizophrenia |
9.1% |
| Convulsion |
6.8% |
| Affective Disorder |
4.5% |
| Epilepsy |
4.5% |
| Psychotic Disorder |
4.5% |
| Asthma |
2.3% |
| Convulsion Prophylaxis |
2.3% |
| Partial Seizures |
2.3% |
| Psychomotor Hyperactivity |
2.3% |
| Psychomotor Skills Impaired |
2.3% |
| Salivary Hypersecretion |
2.3% |
| Schizophrenia, Paranoid Type |
2.3% |
| Urethritis |
2.3% |
| Vitamin D Deficiency |
2.3% |
|
| Drug Interaction |
26.7% |
| Oedema Peripheral |
13.3% |
| Hepatic Enzyme Abnormal |
6.7% |
| Lupus-like Syndrome |
6.7% |
| Neuroleptic Malignant Syndrome |
6.7% |
| Overdose |
6.7% |
| Potentiating Drug Interaction |
6.7% |
| Schizophrenia |
6.7% |
| Somnolence |
6.7% |
| Suicidal Behaviour |
6.7% |
| Toxicity To Various Agents |
6.7% |
|
